drugset / Trial / NCT04745689
Study of AZD2811 + Durvalumab in ES-SCLC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.
Timeline
- Start
- 2021-02-23
- Primary completion
- 2022-06-18
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD2811 | Unknown | — | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Etoposide | Small molecule | — | Intravenous |